51
|
Mahmood A, Rapalli VK, Waghule T, Gorantla S, Dubey SK, Saha RN, Singhvi G. UV spectrophotometric method for simultaneous estimation of betamethasone valerate and tazarotene with absorption factor method: Application for in-vitro and ex-vivo characterization of lipidic nanocarriers for topical delivery. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2020; 235:118310. [PMID: 32251894 DOI: 10.1016/j.saa.2020.118310] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/05/2020] [Revised: 03/04/2020] [Accepted: 03/27/2020] [Indexed: 06/11/2023]
Abstract
The present study elucidates the development of an accurate, precise and simple simultaneous estimation method for the routine analysis of Betamethasone Valerate (BV) and Tazarotene (TZ). This combination is widely used in the treatment of psoriasis. No method has been reported so far for the simultaneous estimation of BV and TZ in topical dosage forms. The method proposed by this study for the quantification of BV and TZ is the Absorption factor method. The developed method was validated as per the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) guideline. The validated method was found to be linear in a concentration range of 10-38 μg/mL and 4-14 μg/mL for BV and TZ respectively with a regression coefficient >0.990. The method was validated for accuracy and precision which revealed the recovery of >99.80% with RSD <2.0. The method was found to be precise with RSD <2% for inter and intraday. The developed method was employed for quantification of BV and TZ in lipid based nanocarriers formulation and their in-vitro drug release samples. Further, the developed method was successfully applied for the estimation of BV and TZ in the ex-vivo skin matrix. This showed that the method can sensitively determine the drugs in aqueous and biological samples.
Collapse
Affiliation(s)
- Arisha Mahmood
- Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Pilani 333031, India
| | - Vamshi Krishna Rapalli
- Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Pilani 333031, India
| | - Tejashree Waghule
- Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Pilani 333031, India
| | - Srividya Gorantla
- Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Pilani 333031, India
| | - Sunil Kumar Dubey
- Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Pilani 333031, India
| | - Ranendra Narayan Saha
- Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Pilani 333031, India; Birla Institute of Technology and Science, Pilani, Dubai Campus, United Arab Emirates
| | - Gautam Singhvi
- Industrial Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science, Pilani Campus, Pilani 333031, India.
| |
Collapse
|
52
|
Panigrahi BK, Nayak AK. Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics. Curr Drug Deliv 2020; 17:558-576. [PMID: 32384030 DOI: 10.2174/1567201817999200508092821] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2019] [Revised: 09/12/2019] [Accepted: 03/13/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND The scope of nanotechnology has been extended to almost every sphere of our daily life. As a result of this, nanocarriers like Carbon Nanotubes (CNTs) are gaining considerable attention for their use in various therapeutic and diagnostic applications. OBJECTIVE The objective of the current article is to review various important features of CNTs that make them as efficient carriers for anticancer drug delivery in cancer therapeutics. METHODS In this review article, different works of literature are reported on various prospective applications of CNTs in the targeting of multiple kinds of cancerous cells of different organs via; the loading of various anticancer agents. RESULTS Actually, CNTs are the 3rd allotropic type of the carbon-fullerenes that are a part of the cylindrical tubular architecture. CNTs possess some excellent physicochemical characteristics and unique structural features that provide an effective platform to deliver anticancer drugs to target specific sites for achieving a high level of therapeutic effectiveness even in cancer therapeutics. For better results, CNTs are functionalized and modified with different classes of therapeutically bioactive molecules via; the formation of stable covalent bonding or by the use of supramolecular assemblies based on the noncovalent interaction(s). In recent years, the applications of CNTs for the delivery of various kinds of anticancer drugs and targeting of tumor sites have been reported by various research groups. CONCLUSION CNTs represent an emerging nanocarrier material for the delivery and targeting of numerous anticancer drugs in cancer therapeutics.
Collapse
Affiliation(s)
- Biman Kumar Panigrahi
- Department of Pharmacology, Seemanta Institute of Pharmaceutical Sciences, Mayurbhanj-757086, Odisha, India
| | - Amit Kumar Nayak
- Department of Pharmaceutics, Seemanta Institute of Pharmaceutical Sciences, Mayurbhanj-757086, Odisha, India
| |
Collapse
|
53
|
Targeted drug-delivery systems in the treatment of rheumatoid arthritis: recent advancement and clinical status. Ther Deliv 2020; 11:269-284. [DOI: 10.4155/tde-2020-0029] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that is characterized by synovial inflammation, cellular infiltration in joints which leads to progressive joint destruction and bone erosion. RA is associated with many comorbidities including pulmonary disease, rheumatoid nodules and can have a pessimistic impact on quality of life. The current therapies of RA treatment comprise conventional, small molecule and biological antirheumatic drugs. Their utility as therapeutic agents is limited because of poor absorption, rapid metabolism and adverse effects (dose-escalation, systemic toxicity, lack of selectivity and safety). To overcome these limitations, the novel drug delivery systems are being investigated. This review has compiled currently approved therapies along with emerging advanced drug-delivery systems for RA treatment. Further, active targeting of therapeutic agents to inflamed joints via folate receptor, CD44, angiogenesis, integrins and other provided an improved therapeutic efficacy in the treatment of RA.
Collapse
|
54
|
Souto EB, Baldim I, Oliveira WP, Rao R, Yadav N, Gama FM, Mahant S. SLN and NLC for topical, dermal, and transdermal drug delivery. Expert Opin Drug Deliv 2020; 17:357-377. [PMID: 32064958 DOI: 10.1080/17425247.2020.1727883] [Citation(s) in RCA: 150] [Impact Index Per Article: 37.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Introduction: From a biopharmaceutical standpoint, the skin is recognized as an interesting route for drug delivery. In general, small molecules are able to penetrate the stratum corneum, the outermost layer of the skin. In contrast, the delivery of larger molecules, such as peptides and proteins, remains a challenge. Nanoparticles have been exploited not only to enhance skin penetration of drugs but also to expand the range of molecules to be clinically used.Areas covered: This review focus on Solid lipid nanoparticles (SLN) and Nanostructured lipid carriers (NLC) for skin administration. We discuss the selection criteria for lipids, surfactants, and surface modifiers commonly in use in SLN/NLC, their production techniques, and the range of drugs loaded in these lipid nanoparticles for the treatment of skin disorders.Expert opinion: Depending on the lipid and surfactant composition, different nanoparticle morphologies can be generated. Both SLN and NLC are composed of lipids that resemble those of the skin and sebum, which contribute to their enhanced biocompatibility, with limited toxicological risk. SLN and NLC can be loaded with very chemically different drugs, may provide a tunable release profile, can be produced in a sterilized environment, and be scaled-up without the need for organic solvents.
Collapse
Affiliation(s)
- Eliana B Souto
- Faculty of Pharmacy, University of Coimbra (FFUC), Coimbra, Portugal.,CEB - Centre of Biological Engineering, University of Minho, Braga, Portugal
| | - Iara Baldim
- CEB - Centre of Biological Engineering, University of Minho, Braga, Portugal.,Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, SP, Brazil
| | - Wanderley P Oliveira
- Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, SP, Brazil
| | - Rekha Rao
- Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, India
| | - Nitesh Yadav
- Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, India
| | - Francisco M Gama
- CEB - Centre of Biological Engineering, University of Minho, Braga, Portugal
| | - Sheefali Mahant
- Department of Pharmaceutical Sciences, Guru Jambheshwar University of Science and Technology, Hisar, India
| |
Collapse
|
55
|
Rapalli VK, Kaul V, Gorantla S, Waghule T, Dubey SK, Pandey MM, Singhvi G. UV Spectrophotometric method for characterization of curcumin loaded nanostructured lipid nanocarriers in simulated conditions: Method development, in-vitro and ex-vivo applications in topical delivery. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2020; 224:117392. [PMID: 31330421 DOI: 10.1016/j.saa.2019.117392] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/27/2019] [Revised: 07/06/2019] [Accepted: 07/14/2019] [Indexed: 06/10/2023]
Abstract
Curcumin the extract obtained from the dried rhizome of turmeric, Curcuma longa is a hydrophobic phenol that delivers numerous pharmacological actions like anti-inflammatory, anti-microbial and anti-oxidant, anti-psoriasis, antidiabetic, anticancer. But curcumin has low bioavailability issues that accompany low aqueous solubility, further, when administered orally, >90% of the drug degrades rapidly in the alkaline medium. Administering the drug topically can bypass the problem as well as first-pass metabolism and therefore delivering the drug at the targeted site of action. Encapsulating curcumin in nanostructured lipid nanocarriers (NLC) is an excellent novel strategy. Further, these NLC provides both the controlled release and helps in the enhanced permeation of the drug through the skin's physiological barrier, stratum corneum. For the NLC characterization, a reliable method must be developed that can accurately and precisely determine the drug content in the formulation and also for its in-vitro and ex-vivo characterization. This experiment describes the analytical validation parameters described as per International Conference of Harmonization guidelines to develop a method using the UV-Visible spectroscopy. The method was developed in two solvent systems i.e. methanol and 6.4 pH phosphate buffer with 1.5% polysorbate 80. Methanol solvent was used for the determination of curcumin in the NLC formulation via determining the encapsulation efficiency and 6.4 pH phosphate buffer with 1.5% polysorbate 80 solvent was used for in-vitro and ex-vivo characterization of the developed NLC formulation (cream and gel). These methods were validated in response to linearity, the limit of detection, the limit of quantification, precision, accuracy, repeatability, and specificity.
Collapse
Affiliation(s)
| | - Vedhant Kaul
- Department of Pharmacy, Birla Institute of Technology & Science, Pilani 333031, India.
| | - Srividya Gorantla
- Department of Pharmacy, Birla Institute of Technology & Science, Pilani 333031, India.
| | - Tejashree Waghule
- Department of Pharmacy, Birla Institute of Technology & Science, Pilani 333031, India.
| | - Sunil Kumar Dubey
- Department of Pharmacy, Birla Institute of Technology & Science, Pilani 333031, India
| | - Murali Monohar Pandey
- Department of Pharmacy, Birla Institute of Technology & Science, Pilani 333031, India
| | - Gautam Singhvi
- Department of Pharmacy, Birla Institute of Technology & Science, Pilani 333031, India.
| |
Collapse
|
56
|
Rapalli VK, Singhvi G, Gorantla S, Waghule T, Dubey SK, Saha RN, Hasnain MS, Nayak AK. Stability indicating liquid chromatographic method for simultaneous quantification of betamethasone valerate and tazarotene in in vitro and ex vivo studies of complex nanoformulation. J Sep Sci 2019; 42:3413-3420. [DOI: 10.1002/jssc.201900538] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2019] [Revised: 08/25/2019] [Accepted: 09/10/2019] [Indexed: 12/11/2022]
Affiliation(s)
- Vamshi Krishna Rapalli
- Industrial Research Laboratory, Department of PharmacyBirla Institute of Technology and Science (BITS) Pilani India
| | - Gautam Singhvi
- Industrial Research Laboratory, Department of PharmacyBirla Institute of Technology and Science (BITS) Pilani India
| | - Srividya Gorantla
- Industrial Research Laboratory, Department of PharmacyBirla Institute of Technology and Science (BITS) Pilani India
| | - Tejashree Waghule
- Industrial Research Laboratory, Department of PharmacyBirla Institute of Technology and Science (BITS) Pilani India
| | - Sunil Kumar Dubey
- Industrial Research Laboratory, Department of PharmacyBirla Institute of Technology and Science (BITS) Pilani India
| | - Ranendra Narayan Saha
- Industrial Research Laboratory, Department of PharmacyBirla Institute of Technology and Science (BITS) Pilani India
- Birla Institute of Technology and Science (BITS) PilaniDubai Campus Dubai UAE
| | | | - Amit Kumar Nayak
- Department of PharmaceuticsSeemanta Institute of Pharmaceutical Sciences Mayurbhanj India
| |
Collapse
|
57
|
Background: Carbon Nanotubes for Targeted Drug Delivery. CARBON NANOTUBES FOR TARGETED DRUG DELIVERY 2019. [DOI: 10.1007/978-981-15-0910-0_1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|